Nucleic acids encoding interleukin-1 inhibitors and...

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0


C435S069100, C435S069900, C435S320100, C435S356000, C435S358000, C435S361000, C435S252300, C435S254110, C435S254200, C530S412000, C536S023100, C536S023500

Reexamination Certificate



Compounds are disclosed having the general formula R1—X—R2, wherein R1and R2are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1and R2may be the same or different. Preferred R1and R2groups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor.

patent: 4935343 (1990-06-01), Allison et al.
patent: 4956381 (1990-09-01), Bollinger et al.
patent: 4968607 (1990-11-01), Dower et al.
patent: 5041554 (1991-08-01), Parker et al.
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5453490 (1995-09-01), Hageman et al.
patent: 5455330 (1995-10-01), Haskill et al.
patent: 5508262 (1996-04-01), Norman, Jr.
patent: 5747072 (1998-05-01), Davidson et al.
patent: 5747444 (1998-05-01), Haskill et al.
patent: 5770401 (1998-06-01), Mullarkey
patent: 0343684 (1989-11-01), None
patent: 0 398 817 (1990-11-01), None
patent: WO 8810299 (1988-12-01), None
patent: WO 8901946 (1989-03-01), None
patent: WO 8911540 (1989-11-01), None
patent: WO 9100742 (1991-01-01), None
patent: WO 9108285 (1991-06-01), None
patent: WO 9117184 (1991-11-01), None
patent: WO 9117249 (1991-11-01), None
patent: WO 9212724 (1992-08-01), None
patent: WO 9216221 (1992-10-01), None
patent: WO 9302692 (1993-02-01), None
patent: WO 9307863 (1993-04-01), None
patent: WO 9308304 (1993-04-01), None
patent: WO 9308819 (1993-05-01), None
patent: WO 9308820 (1993-05-01), None
patent: WO 9318783 (1993-09-01), None
patent: WO 9321946 (1993-11-01), None
patent: WO 9324134 (1993-12-01), None
patent: WO 9406457 (1994-03-01), None
patent: WO 9420517 (1994-09-01), None
patent: WO 9421235 (1994-09-01), None
patent: WO 9421275 (1994-09-01), None
patent: WO 9510298 (1995-04-01), None
patent: WO 9516353 (1995-06-01), None
patent: WO 9516706 (1995-06-01), None
patent: WO 9609323 (1996-03-01), None
Hannum et al., Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor, Nature, 343:336-340, Jan. 1990.*
Eisenberg et al., Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist, Nature, 343:341-346, Jan. 1990.*
Watson et al., Molecular Biology of the Gene, Fourth Ed., Benjamin/Cummings Publishing:Menlo Park, CA, p. 313, 1987.*
Liao et al., Characterization of a human interleukin 1 inhibitor, J. Immunol., 134(6): 3882-3886, Jun. 1985.*
Rosenstreich et al., A human urine-derived interleukin 1 inhibitor, J. Exp. Med., 168: 1767-1779, Nov. 1988.*
Arend et al., “Effects of Immune Complexes on Production by Human Monocytes of Interleukin 1 or Interleukin 1 Inhibitor”, J. Immunol., 134(6):3868-3875 (1985).
Arend et al., “An IL-1 Inhibitor from Human Monocytes”, J. Immunol., 143(6):1851-1858 (1989).
Arend et al., “Biological Properties of Recombinant Human Monocyte-derived Interleukin 1 Receptor Antagonist”, J. Clin. Invest., 85:1694-1697 (May 1990).
Balavoine et al., “Identification of Interleukin 1-like Activity and Inhibitor(s) in Urine from a Patient with Acute Monoblastic Leukemia”, Lymphokine Res., 3(4):233A (Abstract) (1984).
Balavoine et al., “Prostaglandin E2 and Collagenase Production by Fibroblasts and Synovial Cells is Regulated by Urine-derived Human Interleukin 1 and Inhibitor(s)”, J. Clin. Invest., 78:1120-1124 (1986).
Barak et al., “Interleukin 1 inhibitory activity secreted by a human myelomonocytic cell line (M20)”, Eur. J. Immunol., 16:1449-1452 (1986).
Barak et al., “Interleukin 1 Inhibitor: Characterization of Mechanism of Activity”, Lymphokine Res. 7:268 (Abstract No. 1.32) (1988).
Beck et al., “Production of Interleukin 1 and A C1q Induced Interleukin 1 Inhibitor by B-CLL Cells”, RES 1987 Annual Meeting (Abstract No. 232).
Bienkowski et al., “Purification and Characterization of Interleukin 1 Receptor Level Antagonist Proteins from THP-1 Cells”, J. Biol. Chem., 265(24):14505-14511 (1990).
Billingham et al., “Interleukin-1: Its Relevance to Rheumatoid Arthritis”, British J. Rheum., 24 (suppl. 1):25-28 (1985).
Biotechnology Bulletin (1994) Jul. 31, 1994, 13(6):2 (100-199 words).
Bories et al., “Human α 1-Acid Glycoprotein-exposed Macrophages Release Interleukin 1 Inhibitory Activity”, Biochem. and Biophys. Res. Comm., 147(2):710-715 (1987).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”, Science, 247:1306-1310 (1990).
Brown et al., “Mechanism of Action of a Human Interleukin-1 Inhibitor”, J. Leukocyte Biol., 37:688-689 (Abstract) (1985).
Bulletin International d'Informations (Droit et Pharmacie), Sep. 21, 1994, 8/9 p. 89(100-199 words).
Cannon et al., “Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever”, Journal of Infectious Diseases, 161:79-84 (1990).
Carter et al., “Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein”, Nature, 344:633-638 (1990).
Catalano, “Clinical Use of Human Recombinant IL-1 Receptor Antagonist”, Keystone Symposium on Cytokines and Cytokine Receptors, Jan. 31-Feb. 7, 1993, p. 55 (Abstract No. E016).
Cominelli et al., “Interleukin-1 in the pathogenesis of and protection from inflammatory bowel disease”, Biotherapy, 1(4):369-375 (1989).
Cominelli et al., “Regulation of Eicosanoid Production in Rabbit Colon by Interleukin-1”, Gastroenterology, 97(6):1400-1405 (1989).
Cominelli et al., “Interleukin 1 (IL-1) Gene Expression, Synthesis, and Effect of Specific IL-1 Receptor Blockade in Rabbit Immune Complex Colitis”, J. Clin. Invest., 86:972-980 (1990).
Conti et al.,“Human Recombinant Interleukin-1 Receptor Antagonist (hrIL-1ra) Enhances the Stimulatory Effect of Interleukin-2 on Natural Killer Cell Activity Against Molt-4 Target Cells”, Int. J. Immunopharmac, 14(6):987-993 (1992).
Dinarello, “Interleukin-1 and Interleukin-1 Antagonism”, Blood, 77(8):1627-1652 (1991).
Dinarello et al., “Interleukin-1”, Digestive Dieseases & Sciences, 33(3):25S-35S (1988).
Dinarello et al., “Interleukins”, Ann. Rev. Med., 37:173-178 (1986).
Durum et al., “Interleukin 1: An Immunological Perspective”, Ann. Rev. Immunol., 3:263-287 (1985).
Eichacker et al., “The Effects of Human Recombinant Interleukin-1 (IL-1) on Canine Alveolar Neutrophil(N) Number and Lung Function”, Critical Care Medicine, Apr. 1989, p. S58 (Abstract).
Ferrara, “The Role of Interleukin 1 (IL-1) and IL-1 Receptor Antagonist in Graft-Versus-Host Disease”, Keystone Symposium on Cellular Immunity & the Immuno-therapy of Cancer, Mar. 17-24, 1993, p. 96 (Abstract No. NZ 019).
Furutani et al., “Cloning and characterization of the cDNAs for human and rabbit interleukin-1 precursor”, Nucleic Acids Res., 13(16):5869-5882 (1985).
Girardin et al., “Tumor Necrosis Factor and Interleukin-1 in the Serum of Children with Severe Infectious Purpura”, New England Journal of Medicine, 319(7):397-400 (1988).
Hall, “Isolation and partial purification of an inhiitor to interleukin 1”, Chem. Abstr., 105(17):539, abstract No. 151238W (Diss. Abstr. Int. B, 46(12), pt. 1, 4191 (1986).
Hall, “Isolation and Partial Purification of an Inhibitor to Interleukin I,” a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University, VCU, Richmond, VA, pp. 1-218 (Dec. 1985).
Helfman et al., “Identification of clones that encode chicken tropomyosin by direct immunological screening of a cDNA expression library”, Proc. Natl. Acad. Sci. USA, 80:31-35 (1983).
Hill et al., “Interleukin 1: A Regulatory Role in G


Say what you really think

Search for the USA inventors and patents. Rate them and share your experience with other people.


Nucleic acids encoding interleukin-1 inhibitors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acids encoding interleukin-1 inhibitors and..., we encourage you to share that experience with our community. Your opinion is very important and Nucleic acids encoding interleukin-1 inhibitors and... will most certainly appreciate the feedback.

Rate now


Profile ID: LFUS-PAI-O-3448453

All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.